Objective: To test the dose-response effect on low-density lipoprotein cholesterol (LDL-c) of plant sterols (PS) from different sources in a low-fat spread. Methods: Dose responses of soybean oil (BO), tall oil (TO) and a mix of tall oil and rapeseed oil (TO/RP) as fatty acid esters were tested in a parallel design in free-living subjects recruited from the general community who had elevated cholesterol concentrations. Subjects received either control for 6 weeks or 1.6 g PS per day for 3 weeks, then 3.0 g/day for 3 weeks. Results: LDL-c was lowered significantly by consumption of 1.6 g/day of PS (À10.4%, range À7.3 to À11.4%). Increasing the dose to 3.0 g/day modestly reduced LDL-c concentrations further to À14.7%. TO, containing 78% sitosterol, produced an increase in serum sitosterol of 6.5 nmol/ml, while BO, containing only 27% campesterol, produced an increase in serum campesterol of 9.5 nmol/ml in 6 weeks. After PS withdrawal, serum sterols declined by 50% within 2 weeks. Conclusion: Different PS sources were equally effective in lowering serum LDL-c concentrations. The decrease in absolute concentrations of LDL-c was dependent on the baseline concentrations. 
Introduction
A large number of human intervention studies have been performed using plant sterols (PS) or stanols incorporated into different food matrices to study their cholesterollowering effects. These studies are based on unesterified (free) or esterified PS or stanols, where the esterification is mostly based on vegetable-oil-derived fatty acids. Since the first publications of Mattson et al. in 1977 and 1982, in which the efficacy of the ester format was shown, the interest in enriching foods with PS or stanol esters as an effective means of lowering total cholesterol (TC) and lowdensity lipoprotein-cholesterol (LDL-c) has increased. Quite a number of different food formats are now available, such as spreads, yogurts or milks, which can be taken on a daily basis. These foods formats typically provide between 1.5 and 2.5 g/day of PS or stanols from one or more servings, which have been proven to result in a 10-15% LDL-c lowering.
From these studies considered collectively, the effective dose range can be established. It was stated in a recent metaanalysis of 41 studies that increasing the dose of PS or stanols to above 2.5 g/day results in little additional effects on lowering cholesterol (Katan et al., 2003) . A few studies using specific PS sources and formats have also shown a dose response in smaller groups (Weststrate and Meijer, 1998; Hendriks et al., 1999) . However, these studies were based on parallel groups or random assignment to the order of PS dose. One study has examined using PS the effect of four different dose levels from 0.8 to 3.2 g/day in a crossover study but no extra benefit beyond 1.6 g/day was seen. The power of the study was limited, as there were only 22 subjects (Hallikainen et al., 2000) . No study so far has directly compared in a well-powered study the stepwise dose effect of different PS sources on serum lipid parameters and individual non-cholesterol sterol concentrations.
PS are typically sourced from vegetable oils such as soybean oil. Sterol-stanol mixtures such as from tall oil may be converted to 100% stanols via hydrogenation. In both cases, esterification with vegetable-oil-derived fatty acids results in the PS-or stanol-esters used in the final product. There are different sterol sources in addition to the common soybean oil sterols, such as rapeseed oil, or tall oil in the non-hydrogenated form. The typical differences in PS composition from these sources could possibly influence the cholesterol-lowering efficacy or metabolic handling of the sterol. PS themselves are absorbed to minor degree, although the main site of action remains in the gut (Trautwein et al., 2003) , whereas stanols, the fully hydrogenated form of sterols, are absorbed to a much lower extent (Ostlund et al., 2002) . Results of different studies, testing whether sterol/ stanol mixtures influence each others absorption or excretion or metabolic effects are not conclusive (Normén et al., 2000; Nestel et al., 2001; Naumann et al., 2003) . Studies with sterols from less common sources such as sheanut oil or ricebran oil show conflicting results (Weststrate and Meijer, 1998; Sierksma et al., 1999; Vissers et al., 2000; Meijer et al., 2003) . Non-hydrogenated tall oil sterols or stanols in their fatty acid esterified form are not used in the food supply nor have they been studied, so it is important to demonstrate the cholesterol-lowering ability of this novel source. Therefore, studies addressing the effectiveness of different natural sterol/stanol mixtures are still needed.
Elevated serum TC and specifically LDL-c concentrations are established risk markers for coronary heart disease (CHD). However, these markers are not fully predictive and new, independent predictors of CHD are being researched. High-sensitivity C-reactive protein (hsCRP) is such a new predictor of cardiovascular events (Ridker, 2001; Libby and Ridker, 2004) and has been shown to be lowered by statins, although the degree of cholesterol-lowering and the fall in CRP are not correlated (Albert et al., 2001) . To our knowledge, only two studies report effects of PS or stanols intakes on hsCRP (Hallikainen et al., 2005; AbuMweis et al., 2006) . Therefore, the aim of this study was to observe the effects of three different natural sterol/stanol sources, namely soybean oil (BO), tall oil (TO) and a 50/50 mix of tall oil and rapeseed oil (TO/RP), at two different doses (1.6 and 3.0 g/day), on serum lipid and hsCRP concentrations given in sequential 3-week periods. The effects of PS composition and dose on serum non-cholesterol sterols during the intervention and subsequent washout period were analyzed. The kinetic behavior of the major PS found in serum during the washout period was also analyzed. Subjects were not on lipid-lowering medication and had not used PS or stanol-containing foods in the 6 months before the study. They were also free from kidney and liver diseases and had a fasting triglyceride concentration of less than 4.5 mmol/l.
Materials and methods

Subjects
The study was approved by the human ethics committee of CSIRO Human Nutrition and written informed consent was obtained from participants.
Subjects were randomly allocated to treatment groups without measurement of baseline lipids, as with approximately 40 subjects per group no differences were expected in the main plasma lipid parameters (TC and LDL) due to random variation.
Study design
For each spread enriched with the PS sources (BO, TO, TO/ RP) and the control spread, a 6-week intervention period was planned with two consecutive doses (1.6 and 3.0 g/day), each for 3 weeks. The intervention periods were preceded by a 2-week run-in period in which all volunteers received a control low-fat spread identical in composition to a regular commercially available spread. Following the 6-week intervention period, 55 men continued having weekly blood samples for the next 9 weeks to examine the disappearance of PS from serum.
The spreads (control and PS ester containing) were provided by Unilever Research Vlaardingen, The Netherlands. Spreads were dispensed in a double-blind manner in portion packs for daily use. The volunteers reported spread consumption on a daily check sheet and brought all unused portion packs back to the clinic.
Volunteers were instructed to continue their usual diet but no instructions were given as to the pattern of spread usage. They were advised not to cook with study margarine, and asked to spread it on bread, toast, vegetables and potatoes. The margarine was thus always taken with a major meal.
Products PS fatty acid esters were selected from three different sources, that is, BO, TO and a mix of TO with RP sterols (50/50 TO/ RP), differing in their sterol profile (Table 1 ). The PS fatty acid esters were formulated into vegetable oil-based low-fat spreads (47% fat) according to Unilever standard operating procedures. The spreads were packed in 25 g portion packs for individual use. Content uniformity of PS in the portion packs was checked throughout production runs and found to be within 97 and 108% of the target for the 1.6 g dose and between 95 and 106% for the 3.0 g dose. The control product was virtually PS-free and contained only 75 mg PS per serving of 25 g. Weight deviations of individual portion packs were within a 2% band around the target of 25 g per portion pack.
Measurements
Plasma and serum samples were obtained from blood samples after an overnight fast via venepuncture at weekly intervals and on four occasions in the first 2 weeks after withdrawal of PS at the end of the intervention period. From these samples the following data were obtained: serum TC, LDL-c, high-density lipoprotein-cholesterol (HDL-c), triglycerides (TG) and hsCRP. At the start, week 3 and week 6 (end intervention), a range of standard clinical chemistry parameters was measured to assess safety-related effects. Serum sitosterol and campesterol concentrations were measured in all samples of 7-8 subjects in each treatment group. Analysis TC, HDL-c, glucose, hsCRP and liver function tests were measured using a Hitachi auto-analyzer and standard Roche kits (Roche Diagnostics, Basel, Switzerland). LDL-c was measured using a Roche LDL direct kit.
Serum non-cholesterol sterol determination by GC Materials. The reference sterol compounds campesterol, 5a-cholestane, 5a-cholestan-3b-ol, cholesterol, desmosterol, lanosterol, lathosterol, sitostanol, b-sitosterol, and stigmasterol were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia) and brassicasterol from SciTec (Prague, Czech Republic). The Sylon BTZ silylation reagent (Supelco #33030) was obtained from Sigma-Aldrich (Australia). All other reagents were either chromatographic or analytical grade.
Analytical method. The concentrations of the individual sterols in serum were quantified using a modified method as described previously by Wolthers et al. (1991) . The method was based on saponification followed by extraction, silylation and analysis by gas chromatography with flame ionization detection (GC-FID) using an internal standard for calibration as described previously (Clifton et al., 2004) . All analyses were performed on an Agilent 6890N GC equipped with an on-column injector (Agilent Technologies, Sydney, Australia). The column was a capillary column 50 m Â 250 mm internal diameter Â 0.4 mm film thickness CP-Sil-5CB (Varian, Melbourne, Australia). The retention time for the individual sterols was established by spiking serum with the pure compounds. Quantification was performed against the internal standard (5a-cholestane). Relative response factors were determined for each component pure sterol in a mixture that was processed in the same manner as the serum samples. An average response factor was used for calculating all individual sterols.
Method validation. Assay variability was assessed by repeated analysis of a pooled serum sample from the sterol group. The analysis included the full sample preparation as well as the GC separation. The CV for campesterol was 2.6%.
Statistical and pharmacokinetic analyses
Study group sizes were determined from the estimated within-subject standard deviation (s.d.) for TC as found in previous studies (0.3 mmol/l), a minimal expected LDL-c lowering of 0.3 mmol/l and a power of 80% (5% significance levels). The power calculation required numbers of approximately 40 subjects per treatment (PS source) group. Statistical analyses (analysis of variance and analysis of covariance) were performed using SAS software version 9.1 (SAS Institute, Cary, NC, USA).
Data are presented as mean plus s.d. of the mean and 95% confidence intervals (CI) where appropriate.
Serum PS concentrations and their decline upon cessation of the intervention were analyzed for the elimination rate constants (k el ) in a subset of the male volunteers (n ¼ 7-8 per PS source). A two-compartment model was assumed, based on previous observations and the lipophilic nature of PS resulting in a likely distribution into more lipophilic compartments. Parameters were estimated using a nonlinear regression procedure (Proc Nonlin in SAS). The elimination half-lives were calculated from the k el values as t 1/2 ¼ ln 2/k el .
Results
Subjects
In total, 157 subjects were enrolled in the study and 151 male and female subjects completed the 6-week intervention period. Dropouts were not related to the treatment but to intercurrent illness or work commitments. The biometric data of the volunteers who completed the study are presented in Table 2 for each treatment group. No significant Abbreviations: BO, soybean oil; TO, tall oil; TO/RP, tall oil/rapeseed oil.
differences were found within or between treatment groups for gender, age and BMI. Fifty-five men completed the PS washout section of the study.
Compliance
Volunteers reported consumption of the spreads in a daily checklist and brought all unused portion packs back to the clinic. Compliance was greater than 99.5% in all phases.
Background diet
Recording dietary information was not a part of the study protocol, as the assumption was made that with the size of the treatment groups random noise in dietary variation would be equal among groups.
Serum lipids
Individual lipid data were blindly reviewed to detect any outliners or missing data. The overall data set was found to be of high and consistent quality requiring only a few data points either repeating analysis or rejecting (0-3 weeks; 149 subject data sets, 0-6 weeks; 148 data sets). Serum lipid concentrations for both the low-dose (1.6 g/ day) and the high-dose (3.0 g/day) treatment are summarized in Table 3 . Both doses of the three PS sources were equally effective in significantly lowering serum TC and LDL-c concentrations as compared to the control group. TC Abbreviations: BO, soybean oil; HDL-c, high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol; TC, total cholesterol; TG, triglycerides; TO, tall oil; TO/RP mix, 50/50 tall oil/rapeseed oil. Significance levels for the change in the intervention groups, relative to baseline value are indicated between weeks 0-3 and 0-6, after one-way ANOVA and Dunnett multiple comparison (mean and 95% CI) (*Po0.05 compared to control).
concentrations changed by À0.370.7, À0.470.5 and À0.370.5 mmol/l (mean795% CI) (% change corrected for change in the control group: À6.9, À9.6 and À7.5%) with the BO, TO and the TO/RP sources, respectively, after 3 weeks of 1.6 g/day of PS intake. An additional 3 weeks of 3.0 g/day of the same PS sources decreased TC by À0.470.7, À0.670.6 and À0.570.4 mmol/l (mean795% CI) compared to baseline (% change corrected for change in the control group: À7.7, À11.2 and À10.0%). LDL-c concentration changes were similar to changes in TC. An intake of 1.6 g/day of PS for 3 weeks of the BO, TO and the TO/RP sterol mix lowered LDL-c by À0.370.6, À0.370.5 and À0.270.5 mmol/l (% change corrected for change in the control group: À9.1, À11.4 and À7.3%), respectively compared to baseline. Increasing the dose to 3.0 g/day lowered the concentrations by À0.370.6, À0.570.5 and À0.470.4 mmol/l, respectively (% change corrected for change in the control group: À10.4, À14.7 and À11.8%), which was significantly different from the 1.6 g/day dose (Po0.05).
Serum HDL-c concentrations were not significantly altered by either treatment or PS dose as compared with changes in the control group.
In all treatment groups, serum TG concentrations dropped, but the effect was found statistically significant only for the TO treatment group. After 3 weeks, the concentration in the TO group had changed by À0.270.5 mmol/l compared to pretreatment concentrations (-17.4% relative to control, 95% CI ¼ À31.7 to À3.2%; Table 3 ). Increasing the PS dose had only minimal effects and the absolute change remained at À0.24 mmol/l, whereas the relative decrease dropped further to À21.5%.
Adjustment for baseline serum lipid concentrations
Most intervention studies report mean data for changes in serum lipid concentrations with PS or stanol treatment. In this study, a further analysis was performed to assess whether the individual pretreatment (week 0) concentrations have an effect on the changes induced by PS treatment, over 3 (1.6 g/day) or 6 weeks (3.0 g/day). This analysis showed that changes in serum LDL-c concentrations after 3 or 6 weeks were dependent on the baseline concentrations (Figure 1) . At low LDL-c baseline concentrations the PS intervention resulted in a smaller absolute change compared to effects observed at the higher end of the basal LDL-c range.
The efficacy data revealed a clear and significant effect of each PS source intervention on serum lipids. A further statistical analysis to explore other possible factors, which could be related to the observed responses and interindividual changes, did not reveal any other major contributions. The main factor remained the PS treatment with only marginal effects contributing to the overall variance from age, gender or BMI.
Serum non-cholesterol sterol concentrations
Serum samples were analyzed for all the major sterols found in the different PS sources (Table 1) . Campesterol and bsitosterol concentrations increased well above the typical noise found in the baseline concentrations, reflecting normal background dietary intake (Figures 2 and 3) . Campesterol increased by 6.1 nmol/ml and by 9.8 nmol/ml, respectively, compared to baseline with an intake of 1.6 and 3.0 g/day PS from BO being the source with the highest level of campesterol (26.6%). The increase was roughly proportional to the amount ingested. Although the level of sitosterol was threefold higher in the sitosterol-rich TO (77.9%), 1.6 g/day PS from TO increased serum sitosterol from 8.3 nmol/ml to 14.3 nmol/ml and there was no further increase (14.8 nmol/ml) with the PS dose of 3.0 g/day. With the TO/RP mix (63.5% sitosterol), the rise in serum concentration of sitosterol was lower than expected after adjustment for the lower amount of sitosterol in the mix. The serum PS concentrations reached their maximum 2-3 weeks after the dosage change. Serum lathosterol concentrations did not change during the intervention periods either for all three PS sources or for the control group.
After the withdrawal of the intake of PS-enriched spreads, the serum sterol concentrations declined rapidly. After 2 weeks, 52-64% of the increase in serum sterols had disappeared and the elimination phase could be fitted with a two-compartment model for campesterol and sitosterol, except for the BO group where serum levels stayed close to baseline in general. There was no difference between sitosterol and campesterol in the apparent serum clearance rates or half-lives as found upon further pharmacokinetic analysis (Table 4 ). The fast distribution phase has a half-life of the order of 4 days while the terminal washout phase has a half life close to 25 days. The campesterol half-life of 7.3 days found for the TO group might be a mixed value, as the terminal phase could not be calculated. concentration above 10 mg/l was excluded from the data set before statistical analysis (indicated as CRP-10). Serum CRP-10 concentrations were not affected by the 3-week intake of 1.6 g/day of PS for either sterol source (Figure 4 ) Upon increasing the PS dose to 3.0 g/day, the CRP-10 concentrations in each group started to decrease, but owing to large inter-individual variations, differences were not statistically significant as compared to control. The CRP-10 data for combined treatments versus control were a 37.7721.0% lower with a P-value of 0.07.
Serum hsCRP
Clinical chemistry
The clinical chemistry data (liver function tests and homocysteine) after the 3-and 6-week intervention period did not show any significant changes for any treatment type or PS dose (data not shown).
Discussion
Plant-derived sterol mixtures with different compositions were equally effective in lowering serum total and LDL-c. The decrease in serum LDL-c concentrations was on average 7-11% after a 3-week intake of 1.6 g/day. This is equal to effects seen in other PS efficacy studies. Almost doubling the dose to 3.0 g/day, testing in a consecutive design in the same volunteers, led to a significant additional reduction in LDL-c concentration resulting in a total 10-15% decrease as compared with the control treatment. The larger effect on LDL-c lowering, which was consistent in all groups, is in line with the reported dose-response effect reviewed in a metaanalysis of 41 studies (Katan et al., 2003) . Fasting TG concentrations were significantly lower in the group receiving the TO-PS mix, while TG was lower but not statistically significant with the other PS sources. Typically, sterol efficacy studies report no significant effects on TG or HDL-c concentrations. The effect seen in this study cannot be easily explained or supported by a mechanistic insight, although one in vitro study has shown a reduction in very low-density lipoprotein (VLDL) secretion from HepG2 cells by PS (Ho and Pal, 2004) . Therefore, we cannot rule out that these findings are simply by chance. Future studies especially with TO-derived PS are needed to confirm an effect of serum TG.
Serum cholesterol concentrations reflect both cholesterol absorption and de novo synthesis. It can be speculated that inter-individual differences in metabolic handling of cholesterol have an impact on the effect of PS. So far, no PS study has reported an association between the effect of PS intake and the basal serum cholesterol concentration. However, Kesaniemi and Miettinen (1987) and Gylling and Miettinen (1995) have shown a relationship between cholesterol Figure 4 Impact of low-(1.6 mg/day, weeks 0-3) and high-dose (3.0 mg/day, weeks 3-6) PS intake on serum hsCRP concentrations (as % change, corrected for changes in the control group, in normal to mildly hypercholesterolemic subjects. CRP10 ¼ individuals and data points above 10 mg/l were excluded from the analysis, see text. Bars indicate the 95% confidence interval. BO ¼ soybean oil sterols; TO ¼ tall oil sterols; TO/RP ¼ tall oil/rape seed sterol oil mix.
absorption efficiency and LDL-c, which would suggest that PS treatment would be more effective in subjects with high baseline LDL-c concentrations as shown in this study. Detailed analysis of the current data showed that for the various PS sources, the absolute decrease in serum cholesterol was dependent on the pre-study baseline LDL-c concentrations of the participants, which translates into a decrease of about 10% across the whole range.
The inflammation marker hsCRP was measured based on a potential role of PS on the inflammation involved in the pathogenesis of atherosclerosis. Modified PS and stanols have been shown to modify the cholesterol influx and efflux from cells by altering nuclear hormone receptor activity, although it is still under discussion whether such a direct effect on the gene level can be considered one of the key mechanisms of action of PS (Plat and Mensink, 2002; Kaneko et al., 2003; Plosch et al., 2004; Calpe-Berdiel et al., 2005) . The potential effect on nuclear hormone receptors could also influence gene expression of inflammatory mediators such as iNOS, COX-2 and IL-6 (Joseph et al., 2003) . PS or stanols could thus directly have an impact on inflammation and plasma markers of inflammation. It is also known that LXR agonists protect against atherosclerosis (Jaye, 2003) . Simvastatin and fibrates lower hsCRP by direct effects on gene expression, but there is no relationship between the degree of cholesterol lowering and the hsCRP lowering. In this study, no significant effect could be detected on the serum hsCRP concentrations after PS intake, although there was a tendency for a modest decrease with the higher PS intakes. Two previous studies also reported no effects of PS or stanol consumption on hsCRP concentrations (Hallikainen et al., 2005; AbuMweis et al., 2006) , although Devaraj et al. (2006) recently demonstrated that using 1 g twice daily of PS causes a median reduction in hsCRP of 12% (P ¼ 0.02) in a two-factor non-parametric analysis.
With increasing intakes of PS from different natural sources, serum concentrations of sitosterol and campesterol increased, but to a distinct extent depending on the PS source. Other minor non-cholesterol sterols did not change significantly. Across the different PS sources, the maximum ratio of campesterol dosing is about a factor of 3 (9.5 vs 26.6%). Also, the maximum dose ratio for sitosterol vs campesterol is about a factor of 3, that is, 26.6% campesterol in BO and 77.9% sitosterol in TO. However, serum increases do not correlate with the increases in intake, as the absolute serum increase in campesterol is about 9 nmol/ml, whereas for sitosterol, the same serum increase is found but with a three times higher dose.
This can be explained probably by a decreased re-excretion of campesterol via the ABCG5/G8 transporters. Experiments using the double-label method also showed an absorption of 0.5% for sitosterol and 1.9% for campesterol (Ostlund et al., 2002) . This study using a single dose of 600 mg of sterols is clearly different from our chronic feeding study in which a total accumulated dose of about 100 g of PS has been delivered to the gut. Thus, in our study, newly formed VLDL contains PS and this continues after cessation of the PS supplement until the hepatic stores of PS are exhausted.
In this situation, the terminal serum clearance t 1/2 is about 25 days while the half-life of the distribution phase from the rapid pool (t 1/2 only a few days) is in line with the findings by Ostlund et al. (2002) . Earlier experiments with radio-labeled sitosterol also showed a two-compartmental elimination behavior with comparable half-lives of 3.7 for the rapid phase but only 12.7 days for the terminal phase (Salen et al., 1970) . The 95% CI for the terminal-phase half-life is, however, large in our study. The serum PS washout kinetics of the BO study group could not be fitted, as the serum concentrations did not increase significantly from basal values during the intervention.
The study of Ostlund et al. (2002) showed a t 1/2 for campesterol of 4.1 days in contrast to 2.9 days for sitosterol, which is probably again related to a different excretion rate from the hepatocyte into bile via ABCG5/G8 transporters. LDL carries much of the PS and its turnover of about 0.3 pools/day is in line with the acute single-dose PS disappearance studies (Shepherd et al., 1979) . Campesterol excretion is estimated to be at least 2 mg/day based on the abovementioned single-dose studies, but is probably 60 mg/day in our studies over the first 2 weeks based on the probable absorbed dose and the t 1/2 of 2 weeks. Sudhop et al. (2002) measured a clearance rate of 1.23 mg/h for sitosterol and 0.76 mg/h for campesterol with a 9 h intestinal infusion and bile collection. In our study, calculated clearance rates of sitosterol and campesterol are the same and not dependent on the PS source. Elimination from the rapid plasma pool is probably driven by the high intracellular concentrations of PS overcoming any affinity differences in the ABCG5/8 transporters. Serum PS concentrations returned to the preintervention level well within the washout period of 9 weeks. The serum non-cholesterol data obtained with standard analytical methods after relatively normal PS dosing showed that kinetic modeling is possible without the need for labeled materials. The drawback of this approach is the lower sensitivity in contrast to the high specificity, which is exactly the opposite of radiolabeled techniques (Matthan et al., 2000) .
In summary, this study demonstrated that different natural PS sources are equally effective in lowering serum TC and LDL-c concentrations, expanding the potential natural sources of PS for functional foods use. The cholesterol-lowering effect of about 10% reduction observed with a PS intake of 1.6 g/day is in line with many other studies assessing the cholesterol lowering efficacy of PS or stanols. Increasing the PS dose to 3.0 g/day resulted in a further significant lowering of LDL-c; however, doses exceeding 2-2.5 g/day add only a small additional benefit. The decrease in the absolute serum total-and LDL-c concentrations was dependent on the basal concentration at start of the intervention. A higher LDL-c concentration at start resulted in a larger absolute decrease.
Kinetic washout behavior of the main PS followed a twocompartment model and the serum elimination half-lives for each compartment for both sitosterol and campesterol were in line with previously reported findings and independent of the PS source or dose. Increasing the dose of PS to up to 3 g/day results in only a moderate further increase in serum PS concentrations. Serum concentrations return to baseline values within a few weeks after discontinuation.
